Bastide Le Confort Médical SA (BLC) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Bastide Le Confort Médical SA stock €59.34, price €19.50, upside +204.3%, quality 55 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range €14.10 – €50.50 · fair‑value band €25.49 – €103.24 · the €19.50 price screens below the €59.34 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Bastide Le Confort Médical in your weekly email
Every Wednesday you see whether Bastide Le Confort Médical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Bastide Le Confort Médical SA, together with its subsidiaries, engages in the sale and rental of medical equipment in France, the United Kingdom, Belgium, Spain, Canada, the Netherlands, and Italy.
Show moreShow less
It operates in six segments: Respiratory Assistance, Home Care, Healthcare Facilities, Nutrition/Infusion/Diabetes, Stoma Therapy/Urology/Wound Care, and E-commerce.
The company offers reclining chairs, lift chairs, and accessories and tables for armchairs; incontinence products, including sample wait, slip absorbent, adult complete change, incontinence diapers, and onesies, anatomical, male urinary, and right-hand protections, incontinence panties and swimsuits, disposable bed pads, support briefs, slips filets, feminine hygiene products, hygiene incontinence, and washable and reusable briefs and panties for urinary incontinence; and mobility products, such as walkers and rollators, walking sticks, electric scooters, and manual and electric wheelchairs.
It also provides medical equipment comprising heating products, bathroom medical equipment, medical measuring device, medical pillow and cushion, technical support, electrostimulation and circulatory stimulators, pressotherapy device, pedal exerciser for seniors, seniors' telephone, bedside tables, medicalized room, sleep apnea device, natural food supplement, thermal compresses, pedicure and foot care, comfort shoes, first aid products, and wellness and health.
In addition, the company offers professional equipment, which includes consumable for healthcare professionals, hygiene and disinfection, care and dressings, diagnosis and self-checking, and other medical equipment; and rental and services for medical bed, wheelchair, air mattress, patient lift, and verticalizer.
It exports its products. The company was incorporated in 1976 and is headquartered in Caissargues, France. Bastide Le Confort Médical SA operates as a subsidiary of Societe d'Investissement Bastide SAS.
Stock analysis
Bastide Le Confort Médical SA (BLC) currently trades at €19.50, while our model-based Fair Value estimate is €59.34, implying the stock looks roughly 67% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of €135.13 per share, and 20 of the 24 models we run sit above the €19.50 price.
Bear case: the Economic Profit group reads lowest at €23.12, and 4 of the 24 models stay below the price. Data coverage for this calculation is low.
Scenario range: €25.49 (bear) to €103.24 (bull), the price of €19.50 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Bastide Le Confort Médical SA reported revenue of €482M in FY2026 versus €468M in FY2022, a compound +0.7%/yr. Reported net income was €58.1M in FY2026, compounding +43.6%/yr from FY2022.
Key figures
Market cap €143M Micro · P/E ratio 21.2 · P/S ratio 2.55 · EPS (TTM) €0.9200 · Dividend yield 0.4% · Net margin 12.0% · Return on equity 9.9% · Return on assets (EBIT) 6.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 49 out of 100 (low confidence).
What moves the price
The share trades about 29% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 33% fair-value upside, at 204%, BLC screens cheaper than that median.
Fair Value models
Bear€25.49Fair Value €59.34Bull€103.24
Price €19.50 · Upside +204.3%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 4 months old). Earnings retained since then (€0.3327 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−1.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.7%
Start year 2021 (pandemic). Over 10 years: +9.7% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.5%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
≈ +6.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+6.5%
Dividend (yield on the price)0.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.34.1% vs 24.0%, picking up
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 9%
Pace: the 5-year rate starts in 2021 (pandemic)
⚠ Rate on operating basis: 2026 sits 902% above its own trend.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+10.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +8.5% a year for the price.
Compare Bastide Le Confort Médical SA with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 77 stocks
Beats the industry median on 8/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score55 · Above median
Fair Value upside+200.0% · Top 25%
Profitability
Return on equity (12 months)9.9% · Above median
Return on assets10.1% · Top 25%
Net margin (12 months)12.0% · Top 25%
Operating margin (12 months)9.9% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)8.0% · Above median
Dividend yield (12 months)0.4% · Bottom 25%
Balance sheet
Debt / equity2.62× · Highest 25%
Valuation Multiplesvs Medical Distribution median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Bastide Le Confort Médical SA Fair Value". https://www.fairvalue-calculator.com/stock/BLC
Frequently asked questions
Is Bastide Le Confort Médical SA (BLC) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of €59.34 versus a price of €19.50, about +204% upside (undervalued).
What is the fair value of BLC?
Our model-based fair value for Bastide Le Confort Médical SA is €59.34 (as of Nov 7, 2026), built from audited fundamentals. The current price: €19.50.
What is the quality score of BLC?
Bastide Le Confort Médical SA has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bastide Le Confort Médical SA (BLC)?
Our model-based price target is the fair value of €59.34 (as of Nov 7, 2026) from 24 valuation models. Cautious scenario €25.49, optimistic scenario €103.24. It is a calculation from audited fundamentals, not an analyst target.
What is the Bastide Le Confort Médical SA stock forecast for 2026?
Our models put fair value at €59.34, about +204% upside versus a price of €19.50 (undervalued). Cautious scenario €25.49, optimistic scenario €103.24. The calculation is refreshed regularly with new filings.
What is the revenue of Bastide Le Confort Médical SA (BLC)?
Bastide Le Confort Médical SA reported trailing-twelve-month revenue of about €482M (latest available figure, as of Nov 7, 2026).
Does Bastide Le Confort Médical SA pay a dividend?
Bastide Le Confort Médical SA currently shows a dividend yield of 0.41% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Bastide Le Confort Médical SA (BLC)?
Bastide Le Confort Médical SA has a dividend yield of 0.4%.
What growth is priced into Bastide Le Confort Médical SA (BLC)?
For today's price to be fair in a discounted-cash-flow model, Bastide Le Confort Médical SA would have to grow free cash flow by +10.8 % per year for five years (discount rate 13.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +1.7 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of BLC use?
Our models discount Bastide Le Confort Médical SA at 13.0 %: a base by market capitalisation (micro), damped by beta 0.90, country premium for France. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Bastide Le Confort Médical SA that is +10.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.0 %) and the same formula as our fair value.
How much growth has Bastide Le Confort Médical SA (BLC) delivered so far?
Over the past 5 years revenue at Bastide Le Confort Médical SA grew +1.7 % a year. The price currently implies free-cash-flow growth of +10.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Bastide Le Confort Médical SA (BLC) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Bastide Le Confort Médical SA (+10.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Bastide Le Confort Médical SA (BLC)?
The free-cash-flow yield on the price is 21.56 %: that much free cash flow Bastide Le Confort Médical SA produces per unit of market value. When it exceeds the discount rate of our models (13.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Bastide Le Confort Médical SA (BLC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bastide Le Confort Médical SA it is €59.34 per share (as of Nov 7, 2026), against a price of €19.50. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is Bastide Le Confort Médical SA stock overvalued or undervalued in 2026?
As of Nov 7, 2026, BLC trades below its calculated fair value: price €19.50, fair value €59.34, a gap of about +204% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BLC?
No. The price is what the market pays today (€19.50); the fair value is what the company's own numbers justify (€59.34). For Bastide Le Confort Médical SA the two are €39.84 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bastide Le Confort Médical SA worth?
The market values Bastide Le Confort Médical SA at about €143M (market capitalisation, as of Nov 7, 2026). Per share that is €19.50; our models calculate a fair value of €59.34 per share.
What do the bullish and bearish scenarios say about BLC?
Our models span a range for Bastide Le Confort Médical SA: cautious scenario €25.49, base €59.34, optimistic €103.24 per share (as of Nov 7, 2026, price €19.50). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BLC?
Bastide Le Confort Médical SA trades at a price-to-earnings ratio of 21.2 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €59.34 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2017 to 2026), reported earnings: 26.0. Other multiples: PEG 0.9.
What is the PEG ratio of BLC?
The PEG ratio of Bastide Le Confort Médical SA is 0.88 (P/E divided by earnings growth, as of Nov 7, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Bastide Le Confort Médical SA (BLC)?
Balance-sheet figures for Bastide Le Confort Médical SA (as of Nov 7, 2026): return on equity 9.9%, debt of 2.62 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is BLC from its 52-week high?
Bastide Le Confort Médical SA trades at €19.50, about 29% below its 52-week high of €27.45 and 11% above the low of €17.54 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of €59.34 is for.
Which stocks are comparable to Bastide Le Confort Médical SA?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bastide Le Confort Médical SA stock attractive at the current price?
The data as of Nov 7, 2026: price €19.50, calculated fair value €59.34 (+204%), Quality Score 55/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BLC calculated?
We run Bastide Le Confort Médical SA through 24 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of €59.34 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Bastide Le Confort Médical SA currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bastide Le Confort Médical SA (BLC)?
The closing price on Nov 9, 2026 was €19.50. Our model-based fair value is €59.34, about +204% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bastide Le Confort Médical SA right now?
The price is below even our cautious bear case (€25.49). The market is more pessimistic than our downside scenario. The model range is unusually wide (€25.49 to €103.24). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (55/100) at a price below fair value, the discount is the argument here, not the business quality.
Where does the earnings growth of Bastide Le Confort Médical SA (BLC) come from?
Earnings per share at Bastide Le Confort Médical SA grew +16.8 % a year from 2015 to 2026. Broken into its drivers: revenue per share +9.7 %, EBIT margin +2.7 %, tax rate +3.0 %, residual (interest, one-offs) +0.7 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Bastide Le Confort Médical SA
How large is the market capitalisation of Bastide Le Confort Médical SA (BLC)?
The market capitalisation of Bastide Le Confort Médical SA is €143M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bastide Le Confort Médical SA (BLC)?
The price-to-sales ratio of Bastide Le Confort Médical SA is 2.55 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bastide Le Confort Médical SA (BLC)?
Earnings per share at Bastide Le Confort Médical SA are €0.9200 (price ÷ EPS = P/E 21.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Bastide Le Confort Médical SA (BLC)?
The dividend yield of Bastide Le Confort Médical SA is 0.4% (payout 8.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Bastide Le Confort Médical SA (BLC)?
The net margin of Bastide Le Confort Médical SA is 12.0% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bastide Le Confort Médical SA (BLC)?
The return on equity (ROE) of Bastide Le Confort Médical SA is 9.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bastide Le Confort Médical SA (BLC)?
On an EBIT basis the return on assets of Bastide Le Confort Médical SA is 6.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bastide Le Confort Médical SA (BLC)?
The operating margin of Bastide Le Confort Médical SA is 9.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bastide Le Confort Médical SA (BLC)?
Revenue at Bastide Le Confort Médical SA is growing +8.0% versus a year earlier (3y avg −1.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bastide Le Confort Médical SA (BLC)?
Earnings per share at Bastide Le Confort Médical SA are growing +46.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Bastide Le Confort Médical SA (BLC) carry?
The net debt of Bastide Le Confort Médical SA is €251M (fiscal year 2026, ≈ 8.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Bastide Le Confort Médical SA in the live analysis
One click puts Bastide Le Confort Médical SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 7, 2026